Trial Profile
A long-term study to evaluate the safety and anti-tumour activity of olaparib monotherapy after combination with carboplatin and paclitaxel in patients with advanced breast, ovarian or fallopian tube cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 16 Nov 2015
Price :
$35
*
At a glance
- Drugs Olaparib (Primary) ; Carboplatin; Paclitaxel
- Indications Breast cancer; Fallopian tube cancer; Ovarian cancer
- Focus Therapeutic Use
- 16 Nov 2015 New trial record